PMID- 29466960
OWN - NLM
STAT- MEDLINE
DCOM- 20180822
LR  - 20240313
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Feb 21
TI  - High-dose of intravenous immunoglobulin modulates immune tolerance in premature 
      infants.
PG  - 74
LID - 10.1186/s12887-018-1055-5 [doi]
LID - 74
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is commonly used to improve the 
      immunomodulatory effects, although its regulatory effect on premature Treg cells 
      is unclear. The purpose of this study is to study the effect of high dose of IVIG 
      (HD-IVIG) on Treg cells expression and cytokine profile in premature birth. 
      METHODS: Fifty-two premature infants were enrolled in this study and thirty-one 
      premature infants who were suspected to have intrauterine infection received 
      HD-IVIG (1-2 g/kg) at the first day of birth; the remaining 21 premature infants 
      were assigned as the control group. The peripheral blood CD4 + T and foxp3+ Treg 
      cells were checked by flow cytometry, and cytokine concentrations were detected 
      by cytometric bead array. RESULTS: With the gestational age growth, peripheral 
      blood CD4 + T and foxp3+ Treg cells of prematurity gradually declined from 50% to 
      35% and from 8% to 6%, respectively. Meanwhile, HD-IVIG increased the percentage 
      of CD4 + T and foxp3+ Treg cells compared with their baseline levels (p < 0.001). 
      HD-IVIG demonstrated different regulating effects on cytokines secretion, 
      increased IL-17 and TGF-beta, and inhibited IL-6 secretion. CONCLUSION: Our results 
      demonstrated that HD-IVIG not only enhanced the premature immune tolerance, but 
      also suppressed the excessive inflammation response mediated by IL-6. TRIAL 
      REGISTRATION: This study was under the clinical study registration 
      (ChiCTR-ORC-16008872, date of registration, 2016-07-21).
FAU - Liu, Pin
AU  - Liu P
AD  - Pediatrics and Neonatology Department, Zhongnan Hospital of Wuhan University, 
      Donghu road 169, Wuhan, 430071, China.
FAU - Li, Lijun
AU  - Li L
AD  - Pediatrics and Neonatology Department, Zhongnan Hospital of Wuhan University, 
      Donghu road 169, Wuhan, 430071, China.
FAU - Fan, Panpan
AU  - Fan P
AD  - Pediatrics and Neonatology Department, Zhongnan Hospital of Wuhan University, 
      Donghu road 169, Wuhan, 430071, China.
FAU - Zheng, Junwen
AU  - Zheng J
AD  - Pediatrics and Neonatology Department, Zhongnan Hospital of Wuhan University, 
      Donghu road 169, Wuhan, 430071, China.
FAU - Zhao, Dongchi
AU  - Zhao D
AUID- ORCID: 0000-0002-9454-6041
AD  - Pediatrics and Neonatology Department, Zhongnan Hospital of Wuhan University, 
      Donghu road 169, Wuhan, 430071, China. zhao_wh2004@hotmail.com.
LA  - eng
SI  - ChiCTR/ChiCTR-ORC-16008872
GR  - 81670007/National Natural Science Foundation of China/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180221
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Biomarkers/blood
MH  - Cytokines/*blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immune Tolerance/*drug effects/immunology
MH  - Immunoglobulins, Intravenous/administration & dosage/*pharmacology
MH  - Immunologic Factors/administration & dosage/*pharmacology
MH  - Infant, Newborn
MH  - Infant, Premature/blood/*immunology
MH  - Male
MH  - T-Lymphocytes, Regulatory/*drug effects/metabolism
PMC - PMC5822672
OTO - NOTNLM
OT  - Cytokines
OT  - FoxP3+ Treg
OT  - Intravenous immunoglobulin
OT  - Preterm
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by the Ethics 
      Committee of Zhongnan Hospital, Wuhan University (protocol 2,015,019), where the 
      study was performed and all guardians signed the inform consent to publish be 
      included in this study. CONSENT FOR PUBLICATION: Not Applicable. COMPETING 
      INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S 
      NOTE: Springer Nature remains neutral with regard to jurisdictional claims in 
      published maps and institutional affiliations.
EDAT- 2018/02/23 06:00
MHDA- 2018/08/23 06:00
PMCR- 2018/02/21
CRDT- 2018/02/23 06:00
PHST- 2017/02/17 00:00 [received]
PHST- 2018/02/07 00:00 [accepted]
PHST- 2018/02/23 06:00 [entrez]
PHST- 2018/02/23 06:00 [pubmed]
PHST- 2018/08/23 06:00 [medline]
PHST- 2018/02/21 00:00 [pmc-release]
AID - 10.1186/s12887-018-1055-5 [pii]
AID - 1055 [pii]
AID - 10.1186/s12887-018-1055-5 [doi]
PST - epublish
SO  - BMC Pediatr. 2018 Feb 21;18(1):74. doi: 10.1186/s12887-018-1055-5.